Lassogen is developing Lassotides™, a new class of programmable lasso peptides engineered to target G protein-coupled receptors for the treatment of difficult diseases like cancer and autoimmune disorders. By utilizing a proprietary platform for high-throughput production and optimization, Lassogen aims to enhance therapeutic efficacy and stability while addressing the limitations of traditional antibodies and small molecules.
Funding
$5.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases, including cancers and autoimmune disorders, are difficult to treat due to limitations in targeting specific proteins, such as G protein-coupled receptors (GPCRs), with traditional drugs. Existing therapeutic modalities like antibodies and small molecules often lack the necessary efficacy, stability, and selectivity to address these challenging targets effectively.
Solution
Lassogen is developing a novel class of therapeutics called Lassotides™, which are programmable lasso peptides engineered to selectively target GPCRs and other difficult disease targets. These Lassotides™ leverage a unique 3D scaffold structure that combines the advantages of both antibodies and small molecules, overcoming their respective limitations. Lassogen's proprietary platform enables high-throughput production and optimization of these lasso peptides, enhancing their therapeutic efficacy, stability, and safety. By tuning the properties of Lassotides™, Lassogen aims to create potent and selective therapeutics for diseases inadequately treated by existing approaches.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel therapeutics for cancer, autoimmune disorders, and other diseases with difficult-to-target proteins.
Features
- Programmable lasso peptides (Lassotides™) with a unique 3D scaffold structure
- Engineered to target G protein-coupled receptors (GPCRs) and other challenging disease targets
- High-throughput production and optimization platform for rapid development
- Tunable properties for enhanced therapeutic efficacy, stability, and safety
- Designed to overcome the limitations of traditional antibodies and small molecules